Table 2.
Clinical data of SLE patients.
| SLE | Total, n = 32 | ||
|---|---|---|---|
| NPSLE, n = 15 | Non-NPSLE, n = 17 | ||
| Clinical symptoms | |||
| Constitutional | 0 | 2 | 2 |
| Vasculitis | 2 | 2 | 4 |
| Mucocutaneous involvement | 2 | 3 | 5 |
| Neurological involvement | 15 | 0 | 15 |
| Musculoskeletal involvement | 2 | 10 | 12 |
| Cardiorespiratory involvement | 2 | 0 | 2 |
| Renal involvement | 2 | 8 | 10 |
| Hematologic involvement | 2 | 2 | 4 |
| Median (IQR) SLEDAI-2K | 8 (6.00, 14.00) | 5.5 (2.25, 11.75) | 6 (4.00, 12.00) |
| Mean dosage of medication | |||
| Prednisolone | 21.59 (mg/day) (n = 11) | 18.90 (mg/day) (n = 5) | 20.76 (mg/day) (n = 16) |
| Hydroxychloroquine | 360 (mg/day) (n = 10) | 250 (mg/day) (n = 12) | 300 (mg/day) (n = 22) |
| Azathioprine | 50 (mg/day) (n = 2) | 50 (mg/day) (n = 1) | 50 (mg/day) (n = 3) |
| Mycophenolate | 1080 (mg/day) (n = 1) | 0 | 1080 (mg/day) (n = 1) |
| Cyclophosphamide | 500 (mg/month) (n = 1) | 0 | 500 (mg/month) (n = 1) |
| Cyclosporine | 25 (mg/day) (n = 1) | 50 (mg/day) (n = 3) | 43.75 (mg/day) (n = 4) |